PMID- 36943575
OWN - NLM
STAT- MEDLINE
DCOM- 20240320
LR  - 20240320
IS  - 1473-4230 (Electronic)
IS  - 1473-4222 (Linking)
VI  - 23
IP  - 2
DP  - 2024 Apr
TI  - Hyperbaric Oxygen Therapy Attenuated the Motor Coordination and Cognitive 
      Impairment of Polyglutamine Spinocerebellar Ataxia SCA17 Mice.
PG  - 401-417
LID - 10.1007/s12311-023-01548-y [doi]
AB  - Spinocerebellar ataxias (SCAs) are a large and diverse group of 
      autosomal-dominant neurodegenerative diseases. No drugs have been approved for 
      these relentlessly progressive and fatal SCAs. Our previous studies indicate that 
      oxidative stress, neuroinflammation, and neuronal apoptosis are elevated in the 
      SCA17 mice, which are the main therapeutic targets of hyperbaric oxygen treatment 
      (HBOT). HBOT is considered to be an alternative and less invasive therapy for 
      SCAs. In this study, we evaluated the HBOT (2.2 ATA for 14 days) effect and the 
      persistence for the management of SCA17 mice and their wild-type littermates. We 
      found HBOT attenuated the motor coordination and cognitive impairment of SCA17 
      mice and which persisted for about 1 month after the treatment. The results of 
      several biochemistry and liver/kidney hematoxylin and eosin staining show the 
      HBOT condition has no obvious toxicity in the mice. Immunostaining analyses show 
      that the neuroprotective effect of HBOT could be through the promotion of BDNF 
      production and the amelioration of neuroinflammation. Surprisingly, HBOT executes 
      different effects on the male and female SCA17 mice, including the reduction of 
      neuroinflammation and activation of CaMKII and ERK. This study suggests HBOT is a 
      potential alternative therapeutic treatment for SCA17. Accumulated findings have 
      revealed the similarity in disease pathomechanisms and possible therapeutic 
      strategies in polyQ diseases; therefore, HBOT could be an optional treatment as 
      well as the other polyQ diseases.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Chiang, Meng-Ke
AU  - Chiang MK
AD  - Department of Life Science, National Taiwan Normal University, Taipei, Taiwan.
FAU - Lin, Ta-Chun
AU  - Lin TC
AD  - Department of Life Science, National Taiwan Normal University, Taipei, Taiwan.
FAU - Lin, Keng-Hsuan
AU  - Lin KH
AD  - Thoughful Animal Hospital, Taoyuan, Taiwan.
FAU - Chang, Ya-Chin
AU  - Chang YC
AD  - Department of Life Science, National Taiwan Normal University, Taipei, Taiwan.
FAU - Hsieh-Li, Hsiu Mei
AU  - Hsieh-Li HM
AD  - Department of Life Science, National Taiwan Normal University, Taipei, Taiwan. 
      hmhsieh@ntnu.edu.tw.
FAU - Lai, Dar-Ming
AU  - Lai DM
AD  - Division of Neurosurgery, Department of Surgery, National Taiwan University 
      Hospital, Taipei, Taiwan. dmlai@ntu.edu.tw.
LA  - eng
PT  - Journal Article
DEP - 20230321
PL  - United States
TA  - Cerebellum
JT  - Cerebellum (London, England)
JID - 101089443
RN  - 26700-71-0 (polyglutamine)
RN  - 0 (Peptides)
SB  - IM
MH  - Mice
MH  - Male
MH  - Female
MH  - Animals
MH  - *Hyperbaric Oxygenation/methods
MH  - Neuroinflammatory Diseases
MH  - *Cognitive Dysfunction/therapy
MH  - *Spinocerebellar Ataxias/therapy/drug therapy
MH  - *Peptides
OTO - NOTNLM
OT  - Behavior
OT  - Gender
OT  - Hyperbaric oxygen
OT  - Memory
OT  - Spinocerebellar ataxias
EDAT- 2023/03/22 06:00
MHDA- 2024/03/20 06:46
CRDT- 2023/03/21 12:19
PHST- 2023/03/14 00:00 [accepted]
PHST- 2024/03/20 06:46 [medline]
PHST- 2023/03/22 06:00 [pubmed]
PHST- 2023/03/21 12:19 [entrez]
AID - 10.1007/s12311-023-01548-y [pii]
AID - 10.1007/s12311-023-01548-y [doi]
PST - ppublish
SO  - Cerebellum. 2024 Apr;23(2):401-417. doi: 10.1007/s12311-023-01548-y. Epub 2023 
      Mar 21.